Literature DB >> 25671694

A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.

Degang Liu, Donghui Zhou, Bo Wang1, William Eric Knabe, Samy O Meroueh1.   

Abstract

The urokinase receptor (uPAR) is a GPI-anchored cell surface receptor that is at the center of an intricate network of protein-protein interactions. Its immediate binding partners are the serine proteinase urokinase (uPA), and vitronectin (VTN), a component of the extracellular matrix. uPA and VTN bind at distinct sites on uPAR to promote extracellular matrix degradation and integrin signaling, respectively. Here, we report the discovery of a new class of pyrrolone small-molecule inhibitors of the tight ∼1 nM uPAR·uPA protein-protein interaction. These compounds were designed to bind to the uPA pocket on uPAR. The highest affinity compound, namely 7, displaced a fluorescently labeled α-helical peptide (AE147-FAM) with an inhibition constant Ki of 0.7 μM and inhibited the tight uPAR·uPAATF interaction with an IC50 of 18 μM. Biophysical studies with surface plasmon resonance showed that VTN binding is highly dependent on uPA. This cooperative binding was confirmed as 7, which binds at the uPAR·uPA interface, also inhibited the distal VTN·uPAR interaction. In cell culture, 7 blocked the uPAR·uPA interaction in uPAR-expressing human embryonic kidney (HEK-293) cells and impaired cell adhesion to VTN, a process that is mediated by integrins. As a result, 7 inhibited integrin signaling in MDA-MB-231 cancer cells as evidenced by a decrease in focal adhesion kinase (FAK) phosphorylation and Rac1 GTPase activation. Consistent with these results, 7 blocked breast MDA-MB-231 cancer cell invasion with IC50 values similar to those observed in ELISA and surface plasmon resonance competition studies. Explicit-solvent molecular dynamics simulations show that the cooperativity between uPA and VTN is attributed to stabilization of uPAR motion by uPA. In addition, free energy calculations revealed that uPA stabilizes the VTNSMB·uPAR interaction through more favorable electrostatics and entropy. Disruption of the uPAR·VTNSMB interaction by 7 is consistent with the cooperative binding to uPAR by uPA and VTN. Interestingly, the VTNSMB·uPAR interaction was less favorable in the VTNSMB·uPAR·7 complex suggesting potential cooperativity between 7 and VTN. Compound 7 provides an excellent starting point for the development of more potent derivatives to explore uPAR biology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25671694      PMCID: PMC4654616          DOI: 10.1021/cb500832q

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  70 in total

1.  The most common chemical replacements in drug-like compounds.

Authors:  Robert P Sheridan
Journal:  J Chem Inf Comput Sci       Date:  2002 Jan-Feb

2.  Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization.

Authors:  Nicolai Sidenius; Annapaola Andolfo; Riccardo Fesce; Francesco Blasi
Journal:  J Biol Chem       Date:  2002-05-28       Impact factor: 5.157

Review 3.  NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors.

Authors:  Bernd Meyer; Thomas Peters
Journal:  Angew Chem Int Ed Engl       Date:  2003-02-24       Impact factor: 15.336

4.  Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation.

Authors:  Araz Jakalian; David B Jack; Christopher I Bayly
Journal:  J Comput Chem       Date:  2002-12       Impact factor: 3.376

5.  Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.

Authors:  Y Wei; J A Eble; Z Wang; J A Kreidberg; H A Chapman
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

6.  Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo.

Authors:  J A Aguirre-Ghiso; D Liu; A Mignatti; K Kovalski; L Ossowski
Journal:  Mol Biol Cell       Date:  2001-04       Impact factor: 4.138

7.  Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis.

Authors:  H Gårdsvoll; K Danø; M Ploug
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

8.  Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo.

Authors:  Julio A Aguirre Ghiso
Journal:  Oncogene       Date:  2002-04-11       Impact factor: 9.867

9.  EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.

Authors:  David Liu; Julio Aguirre Ghiso; Yeriel Estrada; Liliana Ossowski
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

10.  Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin.

Authors:  L Kjøller; A Hall
Journal:  J Cell Biol       Date:  2001-03-19       Impact factor: 10.539

View more
  14 in total

Review 1.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

2.  Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction.

Authors:  Degang Liu; David Xu; Min Liu; William Eric Knabe; Cai Yuan; Donghui Zhou; Mingdong Huang; Samy O Meroueh
Journal:  Biochemistry       Date:  2017-03-17       Impact factor: 3.162

3.  A novel peptide blocking cancer cell invasion by structure-based drug design.

Authors:  Yuki Yamada; Seiji Kanayama; Fuminori Ito; Noriyuki Kurita; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-07-31

4.  Small-molecule binding sites to explore protein-protein interactions in the cancer proteome.

Authors:  David Xu; Shadia I Jalal; George W Sledge; Samy O Meroueh
Journal:  Mol Biosyst       Date:  2016-07-25

5.  A Computational Investigation of Small-Molecule Engagement of Hot Spots at Protein-Protein Interaction Interfaces.

Authors:  David Xu; Yubing Si; Samy O Meroueh
Journal:  J Chem Inf Model       Date:  2017-08-29       Impact factor: 4.956

6.  Mimicking Intermolecular Interactions of Tight Protein-Protein Complexes for Small-Molecule Antagonists.

Authors:  David Xu; Khuchtumur Bum-Erdene; Yubing Si; Donghui Zhou; Mona K Ghozayel; Samy O Meroueh
Journal:  ChemMedChem       Date:  2017-10-23       Impact factor: 3.466

7.  Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPAR·uPA Interaction.

Authors:  Khuchtumur Bum-Erdene; Degang Liu; David Xu; Mona K Ghozayel; Samy O Meroueh
Journal:  ACS Med Chem Lett       Date:  2020-12-10       Impact factor: 4.345

8.  Oncogenic Mutations Differentially Affect Bax Monomer, Dimer, and Oligomeric Pore Formation in the Membrane.

Authors:  Mingzhen Zhang; Jie Zheng; Ruth Nussinov; Buyong Ma
Journal:  Sci Rep       Date:  2016-09-15       Impact factor: 4.379

9.  Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer.

Authors:  Nunzia Montuori; Ada Pesapane; Francesca W Rossi; Valentina Giudice; Amato De Paulis; Carmine Selleri; Pia Ragno
Journal:  Transl Med UniSa       Date:  2016-11-01

10.  Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.

Authors:  Concetta Di Mauro; Ada Pesapane; Luigi Formisano; Roberta Rosa; Valentina D'Amato; Paola Ciciola; Alberto Servetto; Roberta Marciano; Roberta Clara Orsini; Francesca Monteleone; Nicola Zambrano; Gabriella Fontanini; Adele Servadio; Giuseppe Pignataro; Lucia Grumetto; Antonio Lavecchia; Dario Bruzzese; Antonino Iaccarino; Giancarlo Troncone; Bianca Maria Veneziani; Nunzia Montuori; Sabino De Placido; Roberto Bianco
Journal:  Sci Rep       Date:  2017-08-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.